Abstract: The invention relates to a compound comprising a mitochondrial targeting group linked to group capable of releasing hydrogen sulfide, or a pharmaceutically acceptable salt thereof, for use in the treatment of the human or animal body by surgery or therapy. The invention also relates to the use of the compound in the treatment of a plant, and to certain forms of the compound.

Abstract: Methods of producing a uniformly or substantially uniformly doped relatively large area multi-layered graphene element are described comprising the steps of placing the graphene element and a dopant under low pressure conditions, and holding the graphene element and dopant at an elevated temperature for a period of time while under the low pressure conditions. In one arrangement, openings are formed in a multi-layered graphene element of relatively large area prior to doping. In another arrangement, a relatively large area multi-layered graphene element formed by an epitaxial growth technique is used. The invention also relates to an element produced using the aforementioned techniques.

Abstract: Compounds for use The invention relates to a combination comprising (i) a compound A comprising a mitochondrial targeting group linked to a group capable of releasing hydrogen sulfide or a pharmaceutically acceptable salt thereof or a prodrug thereof, an inhibitor of the thioredoxin antioxidant system or pharmaceutically acceptable salt thereof or a prodrug thereof, and/or a nitroxide or a pharmaceutically acceptable salt thereof or a prodrug thereof; and (ii) a photosensitizer or photosensitizer precursor; for use in photodynamic therapy.

Abstract: The present invention relates to a transparent chemically functionalized graphene with high electrical conductivity and which is stable in air. It also relates to a method of manufacturing a conductive and transparent graphene-based material.

Abstract: A structure for broadband light funneling comprises a two-dimensional periodic array of connected ultrasubwavelength apertures, each aperture comprising a large sub-aperture that aids in the coupling of the incoming incident light and a small sub-aperture that funnels a significant fraction of the incident light power. The structure possesses all the capabilities of prior extraordinary optical transmission platforms, yet operates nonresonantly on a distinctly different mechanism. The structure demonstrates efficient ultrabroadband funneling of optical power confined in an area as small as ˜(?/500)2, where optical fields are enhanced, thus exhibiting functional possibilities beyond resonant platforms.

Abstract: We describe a system/method for predicting the outcome of a medical procedure on a patient. The system/method uses using complement cascade data representing levels of a set of complement cascade markers in the patient at a succession of peri-operative time intervals, determining deviations from a model of the response to provide a pre-symptomatic prediction of the outcome. In embodiments the complement cascade pathways include the lytic pathway and at least one of the lectin pathway, the classical pathway and the alternative pathway, and the biomarkers include at least C3. The system may include an electroluminescence or plasmon-resonance multianalyte detector to analyze a blood sample from the patient.

Abstract: There is provided a NetB epitope polypeptide comprising at least 10 contiguous amino acids from SEQ ID NO:1 and comprising a mutation in at least one position between amino acids 130 and 297 as compared with the equivalent position in SEQ ID NO:3, the mutation preferably being located within a rim domain, the polypeptide being capable of binding an antibody which binds to SEQ ID NO:1 and having reduced toxicity compared with the toxicity of SEQ ID NO:1. The polypeptide is useful to vaccinate a subject against infection by Clostridium perfringens.

Abstract: There is provided an epsilon toxin epitope polypeptide comprising a sequence of at least 10 contiguous amino acids from SEQ ID NO:3, the sequence comprising a mutation of at least one tyrosine residue compared to the equivalent sequence in SEQ ID NO:3, the polypeptide being capable of binding an antibody which binds to SEQ ID NO:5 and having reduced toxicity compared with the toxicity of SEQ ID NO:5. The polypeptide is useful in a method of vaccinating a subject against developing a disease caused by clostridium perfringens and/or caused by (or associated with the presence of) active epsilon toxin.

Abstract: The present invention relates to the field of medicine. It more particularly relates to the use of compounds for preventing and/or treating dyslipidemia in a subject, said dyslipidemia typically being linked to the excess presence in the biological membranes, including in the biological membranes of non-adipocyte cells, of fatty acids, in particular of saturated long-chain fatty acids, and/or of sterols. The invention also relates to compositions, in particular pharmaceutical compositions and food supplements or complements, comprising such compounds, and to the uses thereof for preventing and/or treating dyslipidemia. The compounds and compositions according to the invention can in particular be advantageously used for preventing and/or treating a pathological condition selected from metabolic syndrome and/or a symptom or abnormality characteristic of metabolic syndrome, preferably for preventing or treating type 2 diabetes mellitus or hepatic steatosis.

Abstract: There is provided a NetB epitope polypeptide comprising at least 10 contiguous amino acids from SEQ ID NO:1 and comprising a mutation in at least one position between amino acids 130 and 297 as compared with the equivalent position in SEQ ID NO:3, the mutation preferably being located within a rim domain, the polypeptide being capable of binding an antibody which binds to SEQ ID NO:1 and having reduced toxicity compared with the toxicity of SEQ ID NO:1. The polypeptide is useful to vaccinate a subject against infection by Clostridium perfringens.

Abstract: Methods of producing a uniformly or substantially uniformly doped relatively large area multi-layered graphene element are described comprising the steps of placing the graphene element and a dopant under low pressure conditions, and holding the graphene element and dopant at an elevated temperature for a period of time whilst under the low pressure conditions. In one arrangement, openings are formed in a multi-layered graphene element of relatively large area prior to doping. In another arrangement, a relatively large area multi-layered graphene element formed by an epitaxial growth technique is used. The invention also relates to an element produced using the aforementioned techniques.

Abstract: A compound which is a compound of formula (I) or any salt thereof: wherein R1 is a Ci-C6 alkyl group, R2 is H or a Ci-C6 alkyl group, R3 is H or a Ci-C6 alkyl group, and n is an integer from 0 to 5.

Abstract: A detector is described comprising a first graphene element (12), the first graphene element (12) comprising a few layer graphene element functionally doped with a dopant material and to which at least one electrode is connected.

Abstract: A compound which is a compound of formula (I) or any salt thereof: wherein R1 is a Ci-C6 alkyl group, R2 is H or a Ci-C6 alkyl group, R3 is H or a Ci-C6 alkyl group, and n is an integer from 0 to 5.

Abstract: The invention relates to antibodies to Aspergillus species and to methods of producing those antibodies. The invention also relates to the use of such antibodies in identifying the presence of the Aspergillus species and to methods of treating an infection with the Aspergillus species.

Abstract: Disclosed is a transmissive optical concentrator comprising an elliptical collector aperture and a non-elliptical exit aperture, the concentrator being operable to concentrate radiation incident on said collector aperture. The body of said concentrator may have a substantially hyperbolic external profile. Also disclosed is a photovoltaic cell employing such a concentrator and a photovoltaic building unit comprising an array of optical transmissive concentrators, each having an elliptical collector aperture; and an array of photovoltaic cells, each aligned with an exit aperture of a concentrator, wherein the area between adjacent collector apertures is transmissive to visible radiation.

Abstract: There is provided a NetB epitope polypeptide comprising at least 10 contiguous amino acids from SEQ ID NO:1 and comprising a mutation in at least one position between amino acids 130 and 297 as compared with the equivalent position in SEQ ID the mutation preferably being located within a rim domain, the polypeptide being capable of binding an antibody which binds to SEQ ID NO:1 and having reduced toxicity compared with the toxicity of SEQ ID NO:1. The polypeptide is useful to vaccinate a subject against infection by Clostridium perfringens.

Abstract: A compound of formula (I) wherein R1 to R4 are, for example, each hydrogen, R5 is pyridyl, which has two or more substituents selected, for example, from halogen, C1-C4-alkyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, and cyano; R6 is, for example, hydrogen; R7 is, for example, hydrogen, cyano, hydroxyl, formyl, C1-C4-alkyl, C1-C4-alkoxy, C2-C4-alkenyl, or C2-C4-alkynyl; and A1 to A5 are, independently selected, from, for example, N, and C—H; and its use as a pesticidal agent.

Abstract: The present invention relates to a transparent chemically functionalized graphene with high electrical conductivity and which is stable in air. It also relates to a method of manufacturing a conductive and transparent graphene-based material.

Abstract: We describe a system/method for predicting the outcome of a medical procedure on a patient. The system/method uses using complement cascade data representing levels of a set of complement cascade markers in the patient at a succession of peri-operative time intervals, determining deviations from a model of the response to provide a pre-symptomatic prediction of the outcome. In embodiments the complement cascade pathways include the lytic pathway and at least one of the lectin pathway, the classical pathway and the alternative pathway, and the biomarkers include at least C3. The system may include an electroluminescence or plasmon-resonance multianalyte detector to analyse a blood sample from the patient.